State-of-the-Art Vaccine Design
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 68
Special Issue Editor
Interests: production of designer proteins that contain a large number immunological elements chosen for diverse biomedical applications including serodiagnostics, vaccines and directed antibody production
Special Issue Information
Dear Colleagues,
Research in vaccine design has made significant progress in recent years, leveraging innovative technologies to enhance their efficacy, safety, and accessibility. One major advancement is the use of nucleic acids, such as mRNA and DNA technology, to directly produce the desired antigen within the recipient’s body. Next-generation vaccines, including viral vectors, protein subunits, and nanoparticle-based formulations, are being investigated to stimulate strong, long-lasting immune responses involving B- and T-cells. Computational biology and artificial intelligence are also revolutionizing vaccine design by identifying new antigen targets and optimizing vaccine candidates. Synthetic biology has an important role in developing new adjuvants and delivery systems to enhance vaccine effectiveness. Additionally, efforts are underway to create universal vaccines targeting influenza, coronaviruses, and others providing broader protection against diverse strains. We are inviting submissions for this Special Issue to showcase the latest developments in vaccine design. Research areas can cover all aspects related to advancing knowledge in vaccine development and improving their performance.
I look forward to receiving your contributions.
Dr. D. William Provance, Jr.
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine
- adjuvant
- recombinant antigen
- synthetic biology
- vaccine delivery systems
- universal vaccines
- immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
